Underutilization of antiosteoporotic drugs by orthopedic surgeons for prevention of a secondary osteoporotic fracture

Iba, Kousuke; Takada, Junichi; Hatakeyama, Naoko; Kaya, Mitsunori; Isogai, Satoshi; Tsuda, Hajime; Obata, Hiroyuki; Miyano, Suichi; Yamashita, Toshihiko

doi:10.1007/s00776-006-1050-9

Cited by 19 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These patients have a higher probability of poor outcomes with both recurrent fractures and death. 4,5 Oral bisphosphonates, calcium, and vitamin D are currently the most commonly used and most effective therapies for hip fracture prevention in this population. 6 Although a number of postfracture interventions have been attempted (Table 5), the most successful were those performed in the hospital.…”

Section: Discussionmentioning

confidence: 99%

An Effective Team Approach to Improve Postoperative Hip Fracture Care

Piziak

Rajab

2011

Journal of Orthopaedic Trauma

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

An Effective Team Approach to Improve Postoperative Hip Fracture Care

Piziak

Rajab

2011

Journal of Orthopaedic Trauma

View full text Add to dashboard Cite

show abstract

“…These drugs have been less well-studied in elderly men, but may reduce the risk of vertebral fractures among men [15] and increase bone mineral density and prevent hip fractures in elderly men after stroke [9]. However, previous studies have reported a low use of osteoporosis drugs in the oldest old [16], in nursing homes [17], and for prevention of secondary osteoporotic fractures [18][19][20].…”

Section: Introductionmentioning

confidence: 97%

Undertreatment of osteoporosis in persons with dementia? A population-based study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Because it is asymptomatic, osteoporosis is often underdiagnosed and undertreated, so that most patients who suffer fractures have not received previous antiresorptive therapy. 2,3 Furthermore, treatment for osteoporosis is often associated with low longterm patient compliance and persistence, which can limit the effectiveness of therapy. 4,5 The purpose of this article is to for Osteoporosis and Osteopenia 8 showed that the risk of a first fracture increased by 3% for each advancing year of age (or by 18% for every 5 years).…”

Section: Introductionmentioning

confidence: 99%

Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis

Lewiecki

2009

Journal of Women's Health

View full text Add to dashboard Cite

Postmenopausal osteoporosis is an asymptomatic skeletal disease that is often underdiagnosed and undertreated. Osteoporotic fractures are associated with substantial morbidity and mortality and impaired quality of life-socially, emotionally, and financially. Considering the growing burden of osteoporotic fractures worldwide, there remains an ongoing need for progress in the diagnosis of osteoporosis, identification of individuals at high fracture risk, and treatment to prevent fractures. Adequate intake of calcium and vitamin D is recommended as baseline therapy for osteoporosis prevention and treatment. Available pharmacological agents for the management of postmenopausal osteoporosis may not be appropriate for all women. Oral bisphosphonates are generally considered first-line therapy for patients with osteoporosis, but their use may be limited by gastrointestinal side effects. Other agents include hormone therapy, the selective estrogen receptor modulator (SERM) raloxifene, salmon calcitonin, teriparatide (human recombinant parathyroid hormone), and strontium ranelate (in some countries). Factors that may contribute to poor compliance and persistence with current osteoporosis therapies include drug intolerance, complexity of dosing regimens, and poor understanding of the relative benefit and risk with treatment. Emerging therapies for postmenopausal osteoporosis include novel SERMs (bazedoxifene, lasofoxifene, ospemifene, arzoxifene) and denosumab. Because SERMs can display mixed functional estrogen receptor agonist or antagonist activity depending on the target tissue, they may confer beneficial effects on bone with limited stimulation of other tissues (e.g., breast, endometrium). Clinical investigation of these promising new agents is ongoing to evaluate efficacy and safety, with the goal of developing effective strategies to maximize long-term tolerance, compliance, and persistence with therapy.

show abstract

Underutilization of antiosteoporotic drugs by orthopedic surgeons for prevention of a secondary osteoporotic fracture

Cited by 19 publications

References 18 publications

An Effective Team Approach to Improve Postoperative Hip Fracture Care

An Effective Team Approach to Improve Postoperative Hip Fracture Care

Undertreatment of osteoporosis in persons with dementia? A population-based study

Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis

Contact Info

Product

Resources

About